Featured

Immunotherapy efficacy in absence of antigen presentation? How CD4+ T cells mediate responses

The antitumor efficacy of cancer immunotherapy often relies heavily on CD8+ and CD4+ T cell recognition of tumor antigens presented on MHC molecules. However, investigating settings with low or no tumor MHC expression, Kim and Haerr et al. found that...

Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro transcript circILNb elicits superior antitumor immunity in cold tumors

Niu, Ma, Zhu, and Sun et al. constructed circILNb, a circular RNA encoding a blocking anti-PD-L1 Nb and bioactive IL-15/IL-15Rα, which after purification via a novel biotin-avidin system, was delivere...

Decoding tumor heterogeneity- A spatially informed pan-cancer analysis of the tumor microenvironment

Using scRNAseq, Lodi et al. created a pan-cancer single-cell atlas from 160 patients across 9 cancer types, and identified 70 shared cell subtypes. Two distinct hubs with subtype abundances that posit...

A specific gene expression program underlies antigen archiving by lymphatic endothelial cells in mammalian lymph nodes

Sheridan et al. identified that subcapsular sinus lymphatic endothelial cells (LECs) archive antigens for the longest duration post-immunization, and defined transcriptional signatures associated with...

Antibody Mediated Inhibition of HLA/LILR Interactions Breaks Innate Immune Tolerance and Induces Antitumor Immunity

Leukocyte Ig-like receptors (LILRs) on NK cells bind HLA and inhibit the NK immune response. Panda et al. found that 2 anti-panHLA mAbs bound HLA with high affinity, and sterically hindered binding of...

See all for this week

Previous Digests

CRISPR screens to level up CAR-T therapy

October 8, 2025

One of the major questions in CAR T cell therapy research is how to improve CAR-T expansion, persistence, and functionality to improve clinical responses and prevent relapses. Two recent back-to-back publications in Nature used CRISPR screening methods to detect...

CAR T cells take TROP2 targeting to the next level

October 1, 2025

TROP2 is a fetal oncogene that is expressed in a number of cancer types, and while it can be successfully targeted by antibody–drug conjugates (ADCs), cancer cells often develop ADC resistance, either through loss of expression of the targeted...

All about CICON25!

September 24, 2025

The ACIR team attended the CRI-ENCI Ninth International Cancer Immunotherapy Conference (CICON) 2025 in Utrecht, The Netherlands. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Keynote addressMichel Sadelain...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials